DALLAS, Oct. 11, 2017 -- Dougherty’s Pharmacy, Inc. (OTCQB:MYDP) (the “Company”) today announced that Andrew Komuves, President of Pharmacy Operations, has resigned effective October 5, 2017. In conjunction with Mr. Komuves’ departure, the Company is realigning its pharmacy operations, which have always reported to Mark Heil, President and CFO of Dougherty’s Pharmacy, Inc.
“We appreciate Andy’s five years of service to Dougherty’s and wish him well in all his future endeavors,” said James C. Leslie, the Company’s Chairman of the Board.
“We anticipate a seamless transition of the operations oversight as we will reassign Andy’s various responsibilities to several capable people within the organization,” Leslie said. “Our focus continues to be on the strategic growth and financial enhancement of Dougherty’s. We are stepping up our sales and marketing efforts throughout the organization and are working to build our brand recognition within the market. We believe these operational and marketing initiatives will strengthen our business and lead to enhanced long-term value for our shareholders.”
About Dougherty’s Pharmacy, Inc.
Dougherty’s Pharmacy, Inc. is a retail pharmacy chain focused on successfully acquiring, managing and growing community-based pharmacies in the Southwest Region of the United States. On June 9, 2017, the Company changed its name from Ascendant Solutions, Inc. to Dougherty’s Pharmacy, Inc. to better reflect the corporate vision and operating structure. Dougherty’s currently has approximately $48 million in net operating loss carryforwards which can be used to shelter future income, thus enhancing free cash flow or debt service capabilities. Interested investors can access financials and stock trading information for Dougherty’s at OTCMarkets.com or at www.doughertys.com.
| Contacts: | ||||
| Mark S. Heil | Geralyn DeBusk or Tom Carey | |||
| President and CFO | Halliburton Investor Relations | |||
| 972-250-0945 | 972-458-8000 |


Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 



